Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial

Fertility and Sterility

Volumn 106, Issue 2, 2016, Pages 300-305.e5

  Boostanfar, Robert ^a   Gates, Davis ^b   Guan, Yanfen ^b   Gordon, Keith ^b   McCrary Sisk, Christine ^b   Stegmann, Barbara J ^b  

^a Huntington Reproductive Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Assisted reproductive technology; corifollitropin alfa; frozen thawed embryo transfer; GnRH antagonist; rFSH

Indexed keywords

CORIFOLLITROPIN ALFA; GANIRELIX; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; FERTILITY PROMOTING AGENT; FOLLICLE STIMULATING HORMONE, HUMAN, WITH HCG C-TERMINAL PEPTIDE; FOLLITROPIN; GONADORELIN; HORMONE ANTAGONIST;

ADULT; BLEEDING; CONFERENCE PAPER; CONGENITAL MALFORMATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FOLLOW UP; FREEZE THAWING; HEADACHE; HUMAN; INCIDENCE; INFERTILITY THERAPY; LIVE BIRTH; MAJOR CLINICAL STUDY; MISSED ABORTION; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; VOMITING; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONGENITAL ABNORMALITIES; CRYOPRESERVATION; FERTILITY; IN VITRO FERTILIZATION; INFERTILITY; NIDATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; PREGNANCY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; CONGENITAL ABNORMALITIES; CRYOPRESERVATION; DOUBLE-BLIND METHOD; EMBRYO IMPLANTATION; EMBRYO TRANSFER; FEMALE; FERTILITY; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY; LIVE BIRTH; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84964650680     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2016.03.041     Document Type: Conference Paper

References (11)

1. 1 Trounson, A., Mohr, L., Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature 305 (1983), 707–709.
2. 2 Zeilmaker, G.H., Alberda, A.T., van Gent, I., Rijkmans, C.M., Drogendijk, A.C., Two pregnancies following transfer of intact frozen-thawed embryos. Fertil Steril 42 (1984), 293–296.
3. 3 Centers for Disease Control and Prevention. 2012 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports. 2014, US Department of Health and Human Services, Atlanta.
4. 4 Maheshwari, A., Pandey, S., Shetty, A., Hamilton, M., Bhattacharya, S., Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 98 (2012), 368–377.
5. 5 Roque, M., Lattes, K., Serra, S., Sola, I., Geber, S., Carreras, R., et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril 99 (2013), 156–162.
6. 6 Griesinger, G., Schultz, L., Bauer, T., Broessner, A., Frambach, T., Kissler, S., Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril 95 (2011), 2029–2033.
7. 7 Baird, D.T., Collins, J., Egozcue, J., Evers, L.H., Gianaroli, L., Leridon, H., et al. Fertility and ageing. Hum Reprod Update 11 (2005), 261–276.
8. 8 Younis, J.S., Ovarian aging: latest thoughts on assessment and management. Curr Opin Obstet Gynecol 23 (2011), 427–434.
9. 9 Fauser, B.C., Mannaerts, B.M., Devroey, P., Leader, A., Boime, I., Baird, D.T., Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 15 (2009), 309–321.
10. 10 Boostanfar, R., Shapiro, B., Levy, M., Rosenwaks, Z., Witjes, H., Stegmann, B.J., et al. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertil Steril 104 (2015), 94–103.
11. 11 Devroey, P., Boostanfar, R., Koper, N.P., Mannaerts, B.M., Ijzerman-Boon, P.C., Fauser, B.C., A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24 (2009), 3063–3072.